Press Releases

Date Title and Summary View
Toggle Summary Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--May 14, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019
View HTML
Toggle Summary Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Conference call and webcast today at 4:30 p.m. ET - NEWARK, Calif. --(BUSINESS WIRE)--May 8, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial
View HTML
Toggle Summary Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019
Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET NEWARK, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today
View HTML
Toggle Summary Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing
NEWARK, Calif. --(BUSINESS WIRE)--Apr. 9, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of
View HTML
Toggle Summary SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference
– Unprecedented clinical results for DaxibotulinumtoxinA for Injection (DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17 th Aesthetics & Anti-Aging Medical World Congress in Monte-Carlo – NEWARK, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Revance Therapeutics, Inc.
View HTML
Toggle Summary Revance to Participate in the Needham Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor
View HTML
Toggle Summary Revance Releases Fourth Quarter and Full Year 2018 Results
-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed- -On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019- -Raised approximately $108 million net proceeds from public stock offering on January 22, 2019 -
View HTML
Toggle Summary Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today
View HTML
Toggle Summary Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total 115.0 Million NEWARK, Calif. --(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools